Maverick Capital Ltd. Acquires Shares of 19,150 Celgene Corporation (CELG)

Maverick Capital Ltd. acquired a new stake in shares of Celgene Corporation (NASDAQ:CELG) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 19,150 shares of the biopharmaceutical company’s stock, valued at approximately $2,487,000.

A number of other hedge funds have also modified their holdings of CELG. Sustainable Insight Capital Management LLC purchased a new position in Celgene in the second quarter worth $1,636,000. Gotham Asset Management LLC grew its holdings in Celgene by 6.8% in the second quarter. Gotham Asset Management LLC now owns 168,817 shares of the biopharmaceutical company’s stock worth $21,924,000 after purchasing an additional 10,691 shares during the last quarter. Cornerstone Capital Management Holdings LLC. grew its holdings in Celgene by 14.6% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 212,406 shares of the biopharmaceutical company’s stock worth $27,585,000 after purchasing an additional 27,100 shares during the last quarter. Peapack Gladstone Financial Corp grew its holdings in Celgene by 0.5% in the second quarter. Peapack Gladstone Financial Corp now owns 61,382 shares of the biopharmaceutical company’s stock worth $7,972,000 after purchasing an additional 322 shares during the last quarter. Finally, Janus Henderson Group PLC grew its holdings in Celgene by 4,290.5% in the second quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock worth $1,092,071,000 after purchasing an additional 8,217,433 shares during the last quarter. 80.17% of the stock is currently owned by institutional investors.

In other news, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the sale, the director now owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Terrie Curran sold 1,727 shares of the stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The disclosure for this sale can be found here. 0.95% of the stock is currently owned by corporate insiders.

Shares of Celgene Corporation (NASDAQ:CELG) opened at $106.09 on Friday. Celgene Corporation has a one year low of $94.55 and a one year high of $147.17. The company has a market cap of $80,881.07, a PE ratio of 16.05, a PEG ratio of 0.79 and a beta of 1.78. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.

Celgene (NASDAQ:CELG) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter in the prior year, the company earned $1.58 EPS. Celgene’s revenue was up 10.2% compared to the same quarter last year. research analysts forecast that Celgene Corporation will post 6.67 EPS for the current fiscal year.

Several equities research analysts have recently commented on CELG shares. Cantor Fitzgerald reiterated a “buy” rating and set a $162.00 price objective on shares of Celgene in a research note on Tuesday, September 26th. Robert W. Baird reiterated a “buy” rating and set a $162.00 price objective on shares of Celgene in a research note on Thursday, September 21st. Jefferies Group reiterated a “buy” rating and set a $160.00 price objective on shares of Celgene in a research note on Friday, September 15th. Mizuho lifted their price objective on shares of Celgene from $134.00 to $158.00 and gave the stock a “buy” rating in a research note on Friday, September 15th. Finally, Vetr downgraded shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $146.88 price objective for the company. in a research note on Tuesday, August 29th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, twenty have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $139.57.

TRADEMARK VIOLATION NOTICE: “Maverick Capital Ltd. Acquires Shares of 19,150 Celgene Corporation (CELG)” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark legislation. The correct version of this article can be read at https://ledgergazette.com/2017/12/09/maverick-capital-ltd-acquires-shares-of-19150-celgene-corporation-celg.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply